Skip to content
Peptigraph home

CJC-1295 + Ipamorelin and Tirzepatide Together: What Is Known

CJC-1295 + Ipamorelin and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH + GHRP blendNot FDA approved · research blendCJC-1295 + IpamorelinUnapproved blend of CJC-1295 (no DAC) and ipamorelin; an FDA Drugs@FDA search for the CJC-1295 component returned no matches, so no approved product was found.[14]Growth hormoneGLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[15]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 1 result, 2 Oct 2026).

CJC-1295 + Ipamorelin is not FDA approved, and we have no sourced data on combining it with Tirzepatide.
Each component

Side by side

Showing 11 of 13 fields where the two differ. PCAC vote, Jul 2026, Evidence strength are the same or both unknown.

FieldCJC-1295 + IpamorelinTirzepatide
ClassGHRH + GHRP blendGLP-1 / GIP dual agonist
Also calledCJC/Ipatirz, tirze, Mounjaro, Zepbound
CategoryGrowth hormoneGLP-1 & metabolic
FDA statusNot FDA approved · research blendFDA approved (Mounjaro, Zepbound)
WADAProhibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Anti-doping detection
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeIpamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658approximately 5 dayssubcutaneous · FDA label (Mounjaro)
Human studies we summarised6 human (3 randomized or controlled) of 19 summarised, across ingredients24 human (22 randomized or controlled) of 30 summarised
Typical study doses
Vial sizes sold10 mg5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026; 31 Mar 2026)

What the blend's components have shown

Once-daily CJC-1295 maintained normal body composition and growth in GHRH-knockout mice.[16]

In rats, intranasal ipamorelin had an estimated bioavailability of about 20%.[17]

Tirzepatide in sleep apnea

In the SURMOUNT-OSA trial, apnea-hypopnea index fell by 25.3 events per hour with tirzepatide against 5.3 with placebo.[18]

Zepbound's label says it delays gastric emptying and reports rare cases of pulmonary aspiration in patients on GLP-1 receptor agonists undergoing procedures that need general anesthesia or deep sedation.[19]

Label warning on the tirzepatide side

Tirzepatide's boxed warning concerns rat thyroid C-cell tumours with an undetermined human relevance.[19]

Which CJC-1295 do the human data cover?

A recent review of GH-axis peptides separates CJC-1295 with DAC from CJC-1295 without DAC.[20]

One paper describes CJC-1295 as an analog that binds permanently to albumin after injection, with a half-life of 8 d, so the human data it reports are for that albumin-binding form.[21]

Together

The search for the blend with tirzepatide returned 1 PubMed record, and it is not classed as a study of both.

Calculated from pubmed query (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]); search date 2026-10-02; records returned 1; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key cjc-1295-ipamorelin__tirzepatide); no arithmetic applied.

CJC-1295 has no product listed in Drugs@FDA.[14]

Common questions

Can you take CJC-1295/ipamorelin with tirzepatide?

Nothing in the cited records tests the combination. Zepbound's label says tirzepatide delays gastric emptying.[19]

CJC-1295 ipamorelin vs tirzepatide: what is the difference?

Tirzepatide has a randomised sleep-apnea trial with a measured endpoint, the apnea-hypopnea index. The blend has no trial of its own.[18]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  6. 6Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  7. 7Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  8. 8Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  9. 9These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  11. 11Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  12. 12Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  13. 13PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  15. 15Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
  16. 16Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
  17. 17Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.Xenobiotica; the fate of foreign compounds in biological systems · 1998PMID 9879640Accessed 2 Oct 2026
  18. 18Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.The New England journal of medicine · 2024PMID 38912654Accessed 2 Oct 2026
  19. 19ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  20. 20The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
  21. 21Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026

Found an error? Report a correction.